New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
10:46 EDTWY, JOE, LPX, ADES, MTZ, DNR, WAT, RNA, TPH, ABBHigh option volume stocks: WY TPH RNA WAT DNR MTZ ADES LPX JOE ABB
News For WY;TPH;RNA;WAT;DNR;MTZ;ADES;LPX;JOE;ABB From The Last 14 Days
Check below for free stories on WY;TPH;RNA;WAT;DNR;MTZ;ADES;LPX;JOE;ABB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
10:00 EDTRNAOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Arista Networks (ANET) initiated with a Neutral at Citigroup... Casella Waste (CWST) initiated with a Hold at Stifel... CymaBay Therapeutics (CBAY) initiated with an Outperform at Cowen... Finish Line (FINL) initiated with a Buy at Jefferies... Flamel Technologies (FLML) initiated with an Outperform at Leerink... PTC Therapeutics (PTCT) initiated with an Outperform at Oppenheimer... Paramount Gold & Silver (PZG) initiated with a Buy at Noble Financial... Progressive Waste (BIN) initiated with a Hold at Stifel... Prosensa (RNA) initiated with an Outperform at Oppenheimer... Sangamo (SGMO) initiated with an Overweight at JPMorgan... Sarepta (SRPT) initiated with an Outperform at Oppenheimer... Sucampo (SCMP) initiated with a Buy at Roth Capital.
05:42 EDTWYWeyerhaeuser reports Q2 EPS ex-items 40c, consensus 35c
Subscribe for More Information
July 31, 2014
16:24 EDTRNAProsensa initiated with an Outperform at Oppenheimer
Subscribe for More Information
15:38 EDTWYNotable companies reporting before tomorrow's open
Subscribe for More Information
July 30, 2014
15:52 EDTADESColiseum Capital reports 7.9% stake in Advanced Emissions
On July 23, the Board of Directors of the company appointed Shackelton to the Board along with another new director. Such appointments filled a vacancy created by the Board’s increase by one in the size of the Board from ten to eleven directors and the vacancy created by the retirement of Richard Swanson from the company’s Board. The Board also appointed Shackelton to the Finance Committee of the Board. Shackelton’s term as director will run until the next annual meeting of the company’s stockholders at which directors are elected. Shackelton has not served in any capacity for the company prior to this appointment, and there is no arrangements or understandings between him and any other person pursuant to which he was selected to serve as a director. The Board requested that Shackelton serve as director based on its determination that he qualifies as a “independent director” as such term is defined for purposes of the federal securities laws and the NASDAQ Capital Market.
13:54 EDTRNASarepta surges after FDA says will explore quick approval of DMD drugs
Subscribe for More Information
09:04 EDTRNAFDA says 'willing to explore' accelerated approval for DMD drugs
In response to a White House petition urging the FDA to accelerate approval for safe, effective therapies for children with Duchenne, Janet Woodcock, Director, FDA Center for Drug Evaluation and Research, said in a response, "We are willing to explore the use of all potential pathways for the approval of drugs for Duchenne muscular dystrophy, including accelerated approval, as appropriate." She added, "We share your sense of urgency to make safe and effective drugs available for patients with Duchenne muscular dystrophy as soon as possible. That's why we're actively engaged with a number of drug companies focused on developing new drugs for Duchenne muscular dystrophy, including Sarepta Therapeutics, the company developing eteplirsen, an investigational new drug for Duchenne muscular dystrophy." Shares of Sarepta (SRPT) are trading up 5%, or 97c, to $21.30 in pre-market trading. Yesterday afternoon, Wall Street Journal reported that Sarepta is limiting the role its CEO Chris Garabedian is playing in talks with the FDA. Prosensa (RNA) is also developing a treatment for Duchenne muscular dystroph, or DMD. Reference Link
July 28, 2014
06:35 EDTRNAProsensa upgraded to Buy from Neutral at Roth Capital
Subscribe for More Information
July 24, 2014
14:09 EDTWYWeyerhaeuser, DuPont Pioneer announce technology license agreement
Weyerhaeuser (WY) announced a technology license agreement with DuPont Pioneer (DD) that the company said brings together agricultural and forestry know-how to sustainably improve crop productivity for corn growers.
July 22, 2014
13:05 EDTWATWaters shares should be bought, says Maxim
Subscribe for More Information
09:49 EDTWATWaters acquires REIMS technology from MediMass
Subscribe for More Information
08:53 EDTWATWaters narrows FY14 EPS view to $5.25-$5.40 from $5.25-$5.50
Consensus is $5.31. Organic sales growth at or above mid single digit range. Sees mid-to-high single digit top line growth in 2H. Sees government funded instrument sales in the U.S. increasing in 2H. Says governmental spending in China beginning to improve. Sees sales growth in Q3, Q4 that would result in FY14 constant currency mid single digit growth. Says still working to find a successor to CEO Douglas Berthiaume. Sees FY operating tax rate 14%-15%. Sees currency neutral to sales growth in FY. Sees FY gross margins 58.5%-59%.
08:52 EDTWATWaters sees Q3 EPS $1.22-$1.32, consensus $1.32
Subscribe for More Information
07:06 EDTWATWaters reports Q2 adjusted EPS $1.22, consensus $1.21
Subscribe for More Information
July 21, 2014
05:41 EDTABBVolvo announces partnership with ABB
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use